Cytokine-Based Validation of the Inflammation-Based Risk Score in Patients with ST-Segment Elevation Myocardial Infarction
Journal of Interferon & Cytokine Research · 2025
DOI: 10.1089/jir.2024.0163 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Interferon & Cytokine Research, 2025. Verfasst von Brianda Amezcua-Guerra und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Inflammation, Cytokines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
This study aimed to validate an inflammation-based risk score in patients with ST-segment elevation myocardial infarction (STEMI) by examining their cytokine profiles. Upon admission, patients were evaluated for systemic inflammation using a risk score that assigned points based on specific biomarkers: 1 point for leukocyte count ≥9.3 × 10 3 cells/μL, 2 points for high-sensitivity C-reactive protein (hsCRP) ≥13.0 mg/L, and 3 points for serum albumin ≤3.6 g/dL. Patients were categorized into three groups: no inflammation (0 points, n = 13), mild inflammation (1–2 points, n = 35), and severe inflammation (3–6 points, n = 26). Serum levels of 16 key cytokines were measured. Patients with higher risk scores showed elevated interleukin (IL)-6 levels (19.6 vs. 8.5 vs. 6.8 pg/mL; P = 0.021) and decreased interferon-γ-induced protein-10 (IP-10) levels (73.4 vs. 68.8 vs. 112.2 pg/mL; P = 0.011). IL-6 was positively correlated with hsCRP (ρ 0.307) and negatively correlated with albumin (ρ –0.298), while IP-10 was negatively correlated with leukocyte count (ρ –0.301). No other cytokines showed significant association with the risk score. Higher inflammation scores were also associated with an increased incidence of major adverse cardiovascular events, particularly acute heart failure. This study underscores the association between the inflammation-based risk score and cytokine levels, specifically IL-6 and IP-10, in patients with STEMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
- Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
- Immunology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
- Health Care Department, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexico.
ORCID-Profile: Luis M Amezcua-Guerra
Zitieren
APA
Amezcua-Guerra, B., Amezcua-Castillo, L. M., Guerra-López, J. A., Díaz-Domínguez, K., González-Pacheco, H., & Amezcua-Guerra, L. M. (2025). Cytokine-Based Validation of the Inflammation-Based Risk Score in Patients with ST-Segment Elevation Myocardial Infarction. Journal of Interferon & Cytokine Research. https://doi.org/10.1089/jir.2024.0163
Vancouver
Amezcua-Guerra B, Amezcua-Castillo LM, Guerra-López JA, Díaz-Domínguez K, González-Pacheco H, Amezcua-Guerra LM. Cytokine-Based Validation of the Inflammation-Based Risk Score in Patients with ST-Segment Elevation Myocardial Infarction. Journal of Interferon & Cytokine Research. 2025. doi:10.1089/jir.2024.0163
BibTeX
@article{AmezcuaGuerra2025,
author = {Amezcua-Guerra, Brianda and Amezcua-Castillo, Luis M and Guerra-López, Jazmín A and Díaz-Domínguez, Kietseé and González-Pacheco, Héctor and Amezcua-Guerra, Luis M},
title = {Cytokine-Based Validation of the Inflammation-Based Risk Score in Patients with ST-Segment Elevation Myocardial Infarction},
journal = {Journal of Interferon & Cytokine Research},
year = {2025},
doi = {10.1089/jir.2024.0163}
}
EUVIMED